2. Academic Validation
  3. Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas

Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas

  • Cancers (Basel). 2024 Feb 9;16(4):726. doi: 10.3390/cancers16040726.
Yijun Cheng 1,  Dapeng Wang 1,  Hao Tang 1,  Debing Tong 2,  Weiguo Zhao 1,  Shaojian Lin 1,  Hong Yao 1,  Wenwen Lv 3,  Xun Zhang 4,  Li Xue 1,  Hanbing Shang 1 5,  Zhe Bao Wu 1
Affiliations

Affiliations

  • 1 Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • 2 Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
  • 3 Clinical Research Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
  • 4 Neuroendocrine Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • 5 Department of Neurosurgery, Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Haikou 570312, China.
PMID: 38398117 DOI: 10.3390/cancers16040726
Abstract

Several subtypes of pituitary neuroendocrine tumors (PitNETs), such as acromegaly and Cushing's disease, can result in hypertension. However, whether prolactinoma is associated with this complication remains unknown. Moreover, the effect of treatment with surgery or drugs on blood pressure (BP) is unknown. Herein, a retrospective study reviewed 162 patients with prolactinoma who underwent transsphenoidal surgery between January 2005 and December 2022. BP measurements were performed 1 day before and 5 days after surgery. Accordingly, patients' medical characteristics were recorded. In addition, in situ rat and xenograft nude-mice prolactinoma models have been used to mimic prolactinoma. In vivo BP and serum Prolactin (PRL) levels were measured after cabergoline (CAB) administration in both rats and mice. Our data suggest that surgery can effectively decrease BP in prolactinoma patients with or without hypertension. The BP-lowering effect was significantly associated with several variables, including age, sex, disease duration, tumor size, invasion, dopamine agonists (DAs)-resistance, recurrence, and preoperative PRL levels. Moreover, in situ and xenograft prolactinomas induced BP elevation, which was alleviated by CAB treatment without and with a statistical difference in rats and mice, respectively. Thus, surgery or CAB can decrease BP in prolactinoma, indicating that pre- and postoperative BP management becomes essential.

Keywords

blood pressure; cabergoline; hypertension; prolactin; prolactinoma; surgery.

Figures
Products